- Home
- FNA vs CDXC Comparison
FNA vs CDXC Comparison
Compare FNA & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNA
- CDXC
- Stock Information
- Founded
- FNA 2010
- CDXC 1999
- Country
- FNA United States
- CDXC United States
- Employees
- FNA N/A
- CDXC N/A
- Industry
- FNA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- FNA Health Care
- CDXC Health Care
- Exchange
- FNA Nasdaq
- CDXC Nasdaq
- Market Cap
- FNA 590.6M
- CDXC 546.9M
- IPO Year
- FNA 2021
- CDXC N/A
- Fundamental
- Price
- FNA $10.00
- CDXC $6.82
- Analyst Decision
- FNA Strong Buy
- CDXC Strong Buy
- Analyst Count
- FNA 5
- CDXC 2
- Target Price
- FNA $15.60
- CDXC $8.00
- AVG Volume (30 Days)
- FNA 817.5K
- CDXC 2.8M
- Earning Date
- FNA 11-12-2024
- CDXC 10-31-2024
- Dividend Yield
- FNA N/A
- CDXC N/A
- EPS Growth
- FNA N/A
- CDXC N/A
- EPS
- FNA N/A
- CDXC 0.02
- Revenue
- FNA $244,995,000.00
- CDXC $91,668,000.00
- Revenue This Year
- FNA $17.47
- CDXC $18.64
- Revenue Next Year
- FNA $16.35
- CDXC $20.72
- P/E Ratio
- FNA N/A
- CDXC $351.56
- Revenue Growth
- FNA 18.16
- CDXC 9.95
- 52 Week Low
- FNA $4.65
- CDXC $1.32
- 52 Week High
- FNA $14.79
- CDXC $7.58
- Technical
- Relative Strength Index (RSI)
- FNA 76.69
- CDXC 70.03
- Support Level
- FNA $5.07
- CDXC $6.22
- Resistance Level
- FNA $10.68
- CDXC $7.58
- Average True Range (ATR)
- FNA 0.66
- CDXC 0.63
- MACD
- FNA 0.51
- CDXC 0.17
- Stochastic Oscillator
- FNA 88.80
- CDXC 81.42
About FNA Paragon 28 Inc.
Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, Charcot, fracture fixation, hallux valgus, hammertoe, and flat foot. The company's suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. Geographically the company generates the majority of its revenue from the United States.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.